Pacira BioSciences (PCRX)

• Market cap: $1.04B
• 1 day: -1.31%
• 5 days: 2.6%
• 1 month: 5.46%
• 3 months: 5.25%
• 6 months: 31.71%
• Year to date: 8.18%
• 1 year: 22.44%
• 5 years: -55.96%
• 10 years: -27.01%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Employees: 829